- Report
- May 2024
- 93 Pages
Global
From €2113EUR$2,400USD£1,826GBP
- Report
- May 2024
- 311 Pages
Global
From €2157EUR$2,450USD£1,864GBP
- Report
- May 2023
United States
From €1321EUR$1,500USD£1,141GBP
- Report
- November 2022
- 197 Pages
United States
From €3301EUR$3,750USD£2,853GBP
- Report
- August 2024
- 111 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- January 2023
- 131 Pages
Global
From €2201EUR$2,500USD£1,902GBP
- Report
- September 2025
- 82 Pages
China
From €4094EUR$4,650USD£3,538GBP
- Report
- December 2024
- 168 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- November 2024
- 136 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- October 2024
- 122 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- March 2024
- 145 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- June 2023
- 155 Pages
Global
From €4094EUR$4,650USD£3,538GBP
- Report
- December 2021
- 353 Pages
Global
From €4842EUR$5,500USD£4,185GBP
- Report
- November 2023
- 183 Pages
United States
From €3477EUR$3,950USD£3,005GBP
- Report
- April 2025
- 140 Pages
Global
From €4314EUR$4,900USD£3,728GBP
- Report
- January 2024
- 93 Pages
Europe
From €2597EUR$2,950USD£2,245GBP
- Report
- December 2021
- 296 Pages
Global
From €2311EUR$2,625USD£1,997GBP
€4622EUR$5,250USD£3,995GBP
- Report
- May 2025
- 83 Pages
Europe
From €2861EUR$3,250USD£2,473GBP
From €4314EUR$4,900USD£3,728GBP
From €4314EUR$4,900USD£3,728GBP

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more